Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06477614 | Anti-cancer DC Cell Vaccination to Treat Solid Tumors | recruiting | Phase 1 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04952272 | Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors | recruiting | Phase 1 | 50 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 |
| clinicaltrials |
| NCT06195293 | Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06195384 | Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03778814 | TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04842812 | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors | recruiting | Phase 1 | 40 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05779917 | Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05532696 | Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients | recruiting | Phase 1 / Phase 2 | 61 | Anbogen Therapeutics, Inc.INDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT06081907 | The Efficacy and Safety of IBI363 in Solid Tumors(Promise) | recruiting | Phase 1 / Phase 2 | 430 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT05649345 | TR64 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 19 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT06410092 | Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001 | recruiting | Phase 1 | 44 | Sound Biopharmaceuticals Ltd.INDUSTRY | 1 | May 10, 2024 | clinicaltrials |
| NCT06403735 | A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 250 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT05868174 | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | recruiting | Phase 1 | 36 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT06086522 | Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 54 | Qualigen Theraputics, Inc.INDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT05909241 | A Study of BA1202 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 78 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05263479 | A Study of HS-20089 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 177 | Shanghai Hansoh Biomedical Co., LtdINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06342336 | HS-IT101 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 44 | Qingdao Sino-Cell Biomedicine Co., Ltd.INDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06223256 | A Study of NBL-028 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 270 | NovaRock Biotherapeutics, LtdINDUSTRY | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06314373 | A Study for HSK39775 in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 243 | Xizang Haisco Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06240546 | First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 102 | Luye Pharma Group Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06101082 | A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors | recruiting | Phase 1 | 9 | China Medical University, ChinaOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04165590 | Plasmodium Immunotherapy for Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | CAS Lamvac Biotech Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT03838042 | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | recruiting | Phase 1 / Phase 2 | 91 | University Hospital HeidelbergOTHER | 7 | Feb 7, 2024 | clinicaltrials |
| NCT06245330 | A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06225856 | An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 96 | Shanghai Yuyao Biotech Co., Ltd.INDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06211647 | A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 20 | Ruimin WangOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06166888 | A Study of AK131 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 130 | AkesoINDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT06197139 | A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 20 | Xinlu WangOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06170294 | MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 20 | Peking UniversityOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT05923008 | A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 182 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05940896 | RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression | recruiting | Phase 1 | 24 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT05866692 | A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 156 | TYK Medicines, IncINDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05895825 | A Study of EOC237 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 48 | Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., LtdINDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06072989 | Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors | recruiting | Phase 1 | 24 | Shanghai East HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05631886 | Combination of CAR-DC Vaccine and ICIs in Malignant Tumors | recruiting | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05947487 | CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05911464 | A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 248 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05909436 | Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors | recruiting | Phase 1 / Phase 2 | 107 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05823285 | A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients | recruiting | Phase 1 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05204862 | Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 240 | TiumBio Co., Ltd.INDUSTRY | 2 | Apr 3, 2023 | clinicaltrials |
| NCT05528055 | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 122 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05320588 | A Study in Patients With Advanced Cancers | recruiting | Phase 1 / Phase 2 | 332 | BiOneCure Therapeutics Inc.INDUSTRY | 1 | Jul 19, 2022 | clinicaltrials |
| NCT05392699 | ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy | recruiting | Phase 1 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 22, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jun 27, 2024source: clinicaltrials